Financial PerformanceCorMedix reported robust financial results with total revenues of $39.1M for DefenCath, reflecting growing, durable interest and adoption of DefenCath for infection prevention.
Growth PotentialDefenCath is well-positioned for growth based on achievable guidance, with potential drivers including new contracts and greater protocolization at current customers.
Sales OutlookStrong stock reaction appears to be driven by the company's expectations to generate sales at the high end of its guidance.